Fuji Pharma Co Ltd
TSE:4554

Watchlist Manager
Fuji Pharma Co Ltd Logo
Fuji Pharma Co Ltd
TSE:4554
Watchlist
Price: 1 458 JPY 2.46% Market Closed
Market Cap: 35.4B JPY
Have any thoughts about
Fuji Pharma Co Ltd?
Write Note
Fuji Pharma Co Ltd
/
Income Statement
/
Cost of Revenue

Fuji Pharma Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fuji Pharma Co Ltd
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Fuji Pharma Co Ltd
TSE:4554
Cost of Revenue
-¥27.1B
CAGR 3-Years
-12%
CAGR 5-Years
-5%
CAGR 10-Years
-5%
Takeda Pharmaceutical Co Ltd
TSE:4502
Cost of Revenue
-¥1.5T
CAGR 3-Years
-15%
CAGR 5-Years
-9%
CAGR 10-Years
-12%
Daiichi Sankyo Co Ltd
TSE:4568
Cost of Revenue
-¥420B
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
-6%
Otsuka Holdings Co Ltd
TSE:4578
Cost of Revenue
-¥648.6B
CAGR 3-Years
-11%
CAGR 5-Years
-8%
CAGR 10-Years
-4%
Chugai Pharmaceutical Co Ltd
TSE:4519
Cost of Revenue
-¥337.2B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
-5%
Astellas Pharma Inc
TSE:4503
Cost of Revenue
-¥383.6B
CAGR 3-Years
-16%
CAGR 5-Years
-6%
CAGR 10-Years
-2%
No Stocks Found

Fuji Pharma Co Ltd
Glance View

Market Cap
35.4B JPY
Industry
Pharmaceuticals

Fuji Pharma Co., Ltd. engages in the development, manufacture and sale of pharmaceutical products. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 1,532 full-time employees. The firm is engaged in the manufacture and sale of hormone medicines for obstetrics and gynecology department, as well as injectable drugs for radiological department such as radiopaque dye for urinary tracts and blood vessels through its branches. In addition, the Company purchases its main pharmaceutical ingredients from its main parent company.

Intrinsic Value
2 002.38 JPY
Undervaluation 27%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is Fuji Pharma Co Ltd's Cost of Revenue?
Cost of Revenue
-27.1B JPY

Based on the financial report for Jun 30, 2024, Fuji Pharma Co Ltd's Cost of Revenue amounts to -27.1B JPY.

What is Fuji Pharma Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-5%

Over the last year, the Cost of Revenue growth was -15%. The average annual Cost of Revenue growth rates for Fuji Pharma Co Ltd have been -12% over the past three years , -5% over the past five years , and -5% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 201,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.